Clinical Trial Update: A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 study of CGT4255, a selective ERBB2 inhibitor, in adults with ERBB2-altered advanced solid tumors including breas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• CGT4255

Snippet

Sponsor: Cogent Biosciences, Inc. | Conditions: Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer | Phase 1 | Status: RECRUITING